GPC3 and neoplasm: Molecular profiling and biomarkers have also increasingly been used to refine patient selection and tailor systemic therapy, ensuring patients receive the most effective treatment based on their tumor’s specific characteristics, such as levels of AFP, CTNNB1 mutations, and glypican-3 (GPC3) mutations [109].